CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for ...

Ottawa, Sept. 01, 2025 (GLOBE NEWSWIRE) -- According to Precedence Research, the global CRISPR-based gene editing market size was estimated at USD 3.06 billion in 2024. It is predicted to surpass ...

Austin, June 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Technology Market Size & Growth Analysis: According to SNS Insider, the global CRISPR Technology Market was valued at USD 3.45 billion in 2023 and is ...

The global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This growth is fueled by continuous advancements ...

米国食品医薬品局（FDA）は、バーテックス・ファーマシューティカルズ（Vertex Pharmaceuticals）とCRISPRセラピューティクス（CRISPR Therapeutics）が開発したCasgevy（キャスジェビイ）という遺伝子編集技術治療法を、重篤な血液疾患である輸血依存型β（ベータ）サラセミアの治療に用いることを 承認した。

February 17, 2026 / Sciad Communications / Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou ...

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

As current events have demonstrated, infectious diseases represent a significant global concern. The ability for a novel infectious disease to appear and spread worldwide is greater now than at any ...